The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21339490.
- Also identified by DOI 10.1212/WNL.0b013e31820d9507.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sphingosine 1-phosphate receptors (S1PRs) are G protein-coupled receptors expressed by many cell types, including immune and neural cells. These receptors are promising targets for immunomodulatory and possibly neuromodulatory therapies. Fingolimod (FTY720) is a sphingosine analog that, when phosphorylated, becomes a prototypical S1PR modulator. It has recently been approved as the first oral treatment for relapsing forms of multiple sclerosis in some countries. Fingolimod has documented effects on lymphocyte egress, selectively retaining lymphocytes within the lymph nodes. In addition, fingolimod can enter the CNS and can act on S1PRs expressed by most neural lineages. In this article, we discuss recent results supporting the concept that S1PR modulators may exert neuroprotective and regenerative actions in the CNS as well as having anti-inflammatory effects.
Medical subject headings
- Lysophospholipids
- Neurobiology
- Receptors, Lysosphingolipid
- Signal Transduction
- Sphingosine